Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$33.00 USD
+7.08 (27.31%)
Updated Jun 17, 2024 04:00 PM ET
After-Market: $33.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MIRM 33.00 +7.08(27.31%)
Will MIRM be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for MIRM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MIRM
Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?
Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns
MIRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for MIRM
Mirum stock climbs after positive interim data from liver disease drug
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
12 Health Care Stocks Moving In Monday's Intraday Session
MIRM Makes Bullish Cross Above Critical Moving Average
Mirum Pharmaceuticals: Strong Buy Recommendation on Promising Interim Study Results and Regulatory Potential